Literature DB >> 22936051

Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia.

Catherine L Carmichael1, Donald Metcalf, Katya J Henley, Elizabeth A Kruse, Ladina Di Rago, Sandra Mifsud, Warren S Alexander, Benjamin T Kile.   

Abstract

The transcription factor encoded by the E-twenty-six (ETS)-related gene, ERG, is an essential regulator of hematopoietic stem cell function and a potent human oncoprotein. Enforced expression of ERG in murine hematopoietic cells leads to the development of a well-characterized lymphoid leukemia and a less well-defined non lymphoid disease. To clarify the latter, we generated murine bone marrow chimeras with enforced Erg expression in engrafted hematopoietic progenitor cells. As expected, these mice developed lymphoid leukemia. However, the previously reported non lymphoid disease that developed was shown to be a uniform, transplantable leukemia with both erythroid and megakaryocytic characteristics. In vivo, this disease had the overall appearance of an erythroleukemia, with an accumulation of immature erythroblasts that infiltrated the bone marrow, spleen, liver, and lung. However, when stimulated in vitro, leukemic cell clones exhibited both erythroid and megakaryocytic differentiation, suggesting that transformation occurred in a bipotential progenitor. Thus, in mice, Erg overexpression induces the development of not only lymphoid leukemia but also erythro-megakaryocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936051      PMCID: PMC3458381          DOI: 10.1073/pnas.1213454109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

Review 2.  Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21.

Authors:  Alvin Zipursky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

3.  The proto-oncogene ERG in megakaryoblastic leukemias.

Authors:  Liat Rainis; Tsutomu Toki; John E Pimanda; Ester Rosenthal; Keren Machol; Sabine Strehl; Berthold Göttgens; Etsuro Ito; Shai Izraeli
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

4.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.

Authors:  P H Sorensen; S L Lessnick; D Lopez-Terrada; X F Liu; T J Triche; C T Denny
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

5.  v-myb and v-ets transform chicken erythroid cells and cooperate both in trans and in cis to induce distinct differentiation phenotypes.

Authors:  T Metz; T Graf
Journal:  Genes Dev       Date:  1991-03       Impact factor: 11.361

6.  Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1.

Authors:  Y Ben-David; E B Giddens; K Letwin; A Bernstein
Journal:  Genes Dev       Date:  1991-06       Impact factor: 11.361

7.  Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Authors:  Sébastien Malinge; Meghan Bliss-Moreau; Gina Kirsammer; Lauren Diebold; Timothy Chlon; Sandeep Gurbuxani; John D Crispino
Journal:  J Clin Invest       Date:  2012-02-22       Impact factor: 14.808

8.  An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation.

Authors:  H Ichikawa; K Shimizu; Y Hayashi; M Ohki
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

9.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Authors:  W S Pear; J P Miller; L Xu; J C Pui; B Soffer; R C Quackenbush; A M Pendergast; R Bronson; J C Aster; M L Scott; D Baltimore
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

10.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.

Authors:  W S Alexander; A W Roberts; N A Nicola; R Li; D Metcalf
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

View more
  25 in total

1.  Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.

Authors:  K Nowek; S M Sun; L Bullinger; E M J Bindels; C Exalto; M K Dijkstra; K van Lom; H Döhner; S J Erkeland; B Löwenberg; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

2.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Authors:  Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan
Journal:  Nat Genet       Date:  2016-10-24       Impact factor: 38.330

4.  Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.

Authors:  Keith R Loeb; Bridget T Hughes; Brian M Fissel; Nyka J Osteen; Sue E Knoblaugh; Jonathan E Grim; Luke J Drury; Aaron Sarver; Adam J Dupuy; Bruce E Clurman
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

Review 5.  Genomic landscape of megakaryopoiesis and platelet function defects.

Authors:  Elisa Bianchi; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Rossella Manfredini
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

6.  Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.

Authors:  Ying Xie; Mia Lee Koch; Xin Zhang; Melanie J Hamblen; Frank J Godinho; Yuko Fujiwara; Huafeng Xie; Jan-Henning Klusmann; Stuart H Orkin; Zhe Li
Journal:  Stem Cells       Date:  2017-04-24       Impact factor: 6.277

7.  Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.

Authors:  Jian Zhong Tang; Catherine L Carmichael; Wei Shi; Donald Metcalf; Ashley P Ng; Craig D Hyland; Nancy A Jenkins; Neal G Copeland; Viive M Howell; Zhizhuang Joe Zhao; Gordon K Smyth; Benjamin T Kile; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

8.  Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development.

Authors:  Sachiyo Tsuji-Kawahara; Hiroyuki Kawabata; Hideaki Matsukuma; Saori Kinoshita; Tomomi Chikaishi; Mayumi Sakamoto; Yuri Kawasaki; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.

Authors:  M L Tursky; D Beck; J A I Thoms; Y Huang; A Kumari; A Unnikrishnan; K Knezevic; K Evans; L A Richards; E Lee; J Morris; L Goldberg; S Izraeli; J W H Wong; J Olivier; R B Lock; K L MacKenzie; J E Pimanda
Journal:  Leukemia       Date:  2014-10-13       Impact factor: 11.528

10.  Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.

Authors:  Liat Goldberg; Marloes R Tijssen; Yehudit Birger; Rebecca L Hannah; Sarah J Kinston; Judith Schütte; Dominik Beck; Kathy Knezevic; Ginette Schiby; Jasmine Jacob-Hirsch; Anat Biran; Yoel Kloog; Guido Marcucci; Clara D Bloomfield; Peter D Aplan; John E Pimanda; Berthold Göttgens; Shai Izraeli
Journal:  Blood       Date:  2013-08-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.